CD44 and kidney cancer outlook
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a protein called CD44 in kidney cancer tumors can help predict how the disease will progress. Researchers want to understand if CD44 levels are linked to patient outcomes, which could help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with renal cell carcinoma (kidney cancer).
- You do not have any other type of cancer.
- You had surgery to remove your kidney (nephrectomy) at least 3 years ago and have been followed up since then.
- Your medical records are complete and available for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for “biomarkers,” which are measurable signs (often from blood or tissue), to better understand kidney cancer. It may help doctors identify who has kidney cancer and how it behaves.
This trial uses advanced imaging and genetic tests to understand how colon cancer and chronic kidney disease may be connected. It may help decide the best treatment for people with both conditions.
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
This study looks at genetic features of kidney cancer by testing tumor samples. The goal is to find biomarkers—specific signs—that may help predict what kind of kidney cancer it is.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
This trial uses a special imaging drug that targets CD70 (a protein on some kidney cancer cells) to see if it can better detect and track kidney tumors. It may help doctors understand how much cancer is present and guide treatment decisions.
Hear when a new Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.